Future of High-Density Lipoprotein Infusion Therapies: Potential for Clinical Management of Vascular Disease

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Circulation

• Publication date

  2013-09-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.113.002683PMID 24002713
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol: Where Do These Agents Stand in the Approval Process?

  2015cited by this paper
• Biomarkers, putative surrogates, surrogates, and decision making.

  2013cited by this paper
• Update on acute coronary syndromes: the pathologists' view.

  2013cited by this paper
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

  2013cited by this paper
• Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

  2012cited by this paper
• Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

  2012cited by this paper
• Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS.

  2012cited by this paper
• Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?

  2012cited by this paper
• Acute Coronary Events

  2012cited by this paper
• Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein.

  2012cited by this paper
• Inflammation modulates human HDL composition and function in vivo.

  2012cited by this paper
• Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

  2012influential reference
• Effects of dalcetrapib in patients with a recent acute coronary syndrome.

  2012cited by this paper
• High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction.

  2012cited by this paper
• High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics

  2012cited by this paper
• Abstract 11855: CSL112, a Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Healthy Subjects: A, Placebo-Controlled, Double-Blinded, Randomized Single Ascending Dose Study

  2012cited by this paper
• Elevation of Plasma High-Density Lipoproteins Inhibits Development of Experimental Abdominal Aortic Aneurysms

  2012cited by this paper
• The emerging role of HDL in glucose metabolism

  2012cited by this paper
• Abstract 18667: Anti-atherosclerotic Effect of CER-001, an Engineered HDL-mimetic, in the High-fat Diet-fed LDLr Knockout Mice

  2012cited by this paper
• Abstract 11892: Safety and Pharmacokinetics of a Novel Formulation of Human Apolipoprotein A-I (CSL112) in Healthy Subjects: Results of a Placebo-Controlled, Randomized Multiple Ascending Dose Study

  2012cited by this paper
• The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

  2012cited by this paper
• CSL112, A NOVEL FORMULATION OF HUMAN APOA-I, RAPIDLY ACTIVATES LECITHIN-CHOLESTEROL ACYLTRANSFERASE UPON INFUSION INTO RABBITS AND MONKEYS

  2012cited by this paper
• Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes.

  2012cited by this paper
• The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?

  2012cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

  2011cited by this paper
• Recombinant High-Density Lipoprotein Formulations

  2011cited by this paper
• Effect of two intensive statin regimens on progression of coronary disease.

  2011cited by this paper
• Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus

  2011cited by this paper
• Abstract 15525: CER-001, a Synthetic HDL-Mimetic, Safely Mobilizes Cholesterol in Healthy Dyslipidemic Volunteers

  2011cited by this paper
• Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

  2011cited by this paper
• HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells

  2011cited by this paper
• A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome.

  2010cited by this paper
• Effects of High-Density Lipoproteins on Pancreatic &bgr;-Cell Insulin Secretion

  2010cited by this paper
• Importance of macrophage cholesterol content on the flux of cholesterol mass

  2010cited by this paper
• Apolipoprotein A-I structural organization in high density lipoproteins isolated from human plasma

  2010cited by this paper
• Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities

  2010cited by this paper
• Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function

  2009cited by this paper
• Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

  2009cited by this paper
• Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux

  2009cited by this paper
• Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent

  2009cited by this paper
• High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus

  2009influential reference
• Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I

  2009cited by this paper
• HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis

  2009cited by this paper
• Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

  2009cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events

  2008cited by this paper
• Clinical trials report

  2008cited by this paper
• Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus

  2008cited by this paper
• Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque

  2008cited by this paper
• Measurement and determinants of infrarenal aortic thrombus volume

  2008cited by this paper
• Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-IMilano

  2008cited by this paper
• β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment

  2007cited by this paper
• Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

  2007cited by this paper
• HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles: Relevance to Antiapoptotic and Antioxidative Activities

  2007cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.

  2007cited by this paper
• Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes.

  2007cited by this paper
• Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.

  2006cited by this paper
• Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano.

  2006cited by this paper
• Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.

  2006cited by this paper
• mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

  2003cited by this paper
• Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein

  2003cited by this paper
• High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men

  2002cited by this paper
• Metabolism of ApoA-I as Lipid-Free Protein or as Component of Discoidal and Spherical Reconstituted HDLs: Studies in Wild-Type and Hepatic Lipase Transgenic Rabbits

  2002cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

  2001cited by this paper
• Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans.

  2001cited by this paper
• Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans.

  1999cited by this paper
• Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux*

  1997cited by this paper
• Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

  1996cited by this paper

• Apolipoprotein M: Structural Insights, Functional Roles and Therapeutic Approaches in Vascular Disease.

  2026cites this paper
• Radiolabeling lipoproteins to study and manage disease

  2025cites this paper
• Biomarkers of Pre-eclampsia in Pregnant Women With Gestational Diabetes and Pre-existing Type 2 Diabetes: A Systematic Review

  2024cites this paper
• Very low HDL levels: clinical assessment and management

  2023cites this paper
• Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity

  2022cites this paper
• ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

  2022cites this paper
• Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics.

  2022cites this paper
• Beneficial effects of high-density lipoprotein (HDL) on stent biocompatibility and the potential value of HDL infusion therapy following percutaneous coronary intervention

  2022cites this paper
• Multivalent Display of ApoAI Peptides on the Surface of Tobacco Mosaic Virus Nanotubes Improves Cholesterol Efflux.

  2022cites this paper
• Extracellular vesicle therapeutics from plasma and adipose tissue.

  2021cites this paper
• Associations of Monocytes and the Monocyte/High-Density Lipoprotein Ratio With Extracranial and Intracranial Atherosclerotic Stenosis

  2021cites this paper
• Apolipoprotein Mimetic Peptide Inhibits Neutrophil-Driven Inflammatory Damage via Membrane Remodeling and Suppression of Cell Lysis.

  2021cites this paper
• Artificial high-density lipoprotein-mimicking nanotherapeutics for the treatment of cardiovascular diseases.

  2021cites this paper
• Co-administration of CSL112 (apolipoprotein A-I [human]) with atorvastatin and alirocumab is not associated with increased hepatotoxic or toxicokinetic effects in rats.

  2021cites this paper
• Association of Monocytes and the Monocyte/high-density Lipoprotein Ratio With Intracranial and Extracranial Atherosclerotic Stenosis

  2020cites this paper
• Lipoprotein-based drug delivery.

  2020cites this paper
• Administration of eicosapentaenoic acid may alter lipoprotein particle heterogeneity in statin-treated patients with stable coronary artery disease: A pilot 6-month randomized study.

  2020cites this paper
• The effect of processed Tempeh gembus to high sensitivity c-reactive protein (hsCRP) and high-density lipoprotein (HDL) levels in women with obesity

  2020cites this paper
• Novel association between FOXO3 rs2232365 polymorphism and late-onset preeclampsia: a case-control candidate genetic study

  2020cites this paper
• Administration of eicosapentaenoic acid may alter high-density lipoprotein heterogeneity in statin-treated patients with stable coronary artery disease: A 6-month randomized trial.

  2020influential citation
• Maternal lipids, BMI and IL-17/IL-35 imbalance in concurrent gestational diabetes mellitus and preeclampsia.

  2018cites this paper
• Pharmacological Targets for Correction of Dyslipidemias. Opportunities and Prospects of Therapeutic Use

  2018cites this paper
• Impact of intermittent fasting on the lipid profile: Assessment associated with diet and weight loss.

  2018cites this paper
• Impact of Lipoproteins on Atherobiology: Emerging Insights.

  2018cites this paper
• [Pharmacological targets for dislipidemies correction. Opportunities and prospects of therapeutic usage].

  2018cites this paper
• HDL as a Target for Glycemic Control.

  2017cites this paper
• Therapies Targeting HDLc Levels and HDL Function

  2017cites this paper
• Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.

  2017cites this paper
• High-density lipoprotein delivered after myocardial infarction increases cardiac glucose uptake and function in mice

  2017cites this paper
• Rationally designed ligand‐independent peptide inhibitors of TREM‐1 ameliorate collagen‐induced arthritis

  2017cites this paper
• Better Indigenous Risk stratification for Cardiac Health study (BIRCH) protocol: rationale and design of a cross-sectional and prospective cohort study to identify novel cardiovascular risk indicators in Aboriginal Australian and Torres Strait Islander adults

  2017cites this paper
• Solution structure of discoidal high-density lipoprotein particles with a shortened apolipoprotein A-I

  2016cites this paper
• Therapeutic applications of reconstituted HDL: When structure meets function.

  2016cites this paper
• Does high-density lipoprotein protect vascular function in healthy pregnancy?

  2016cites this paper
• Targeting SR-BI for Cancer Diagnostics, Imaging and Therapy

  2016cites this paper
• High-Density Lipoprotein Infusion Therapy and Atherosclerosis: Current Research and Future Directions

  2016influential citation
• Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.

  2016cites this paper
• Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion Protein.

  2016cites this paper
• Can phosphatidylserine enhance atheroprotective activities of high-density lipoprotein?

  2016cites this paper
• Dietary guidelines for saturated fatty acids are not supported by the evidence

  2016cites this paper
• Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering

  2016cites this paper
• Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications.

  2016cites this paper
• Frequencies of apolipoprotein E alleles in depressed patients undergoing hemodialysis – a case-control study

  2015cites this paper
• Immune-mediated and lipid-mediated platelet function in atherosclerosis

  2015cites this paper
• Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein

  2015cites this paper
• HDL and glucose metabolism: current evidence and therapeutic potential

  2015cites this paper
• The role of the lymphatic system in cholesterol transport

  2015influential citation
• Implications of reverse cholesterol transport: recent studies.

  2015cites this paper
• Ongoing challenges for pharmacotherapy for dyslipidemia

  2015cites this paper
• HDL-mediated mechanisms of protection in cardiovascular disease.

  2014cites this paper
• The HDL paradox: what does it mean and how to manage low serum HDL cholesterol level?

  2014influential citation
• Effects of heavy alcohol intake on lipoproteins, adiponectin and cardiovascular risk

  2014cites this paper
• Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy

  2014cites this paper
• The Ebbs and Flows in the Development of Cholesterol‐Lowering Drugs: Prospects for the Future

  2014cites this paper
• High-density lipoprotein, beta cells, and diabetes .

  2014cites this paper
• HDL-targeted therapies: progress, failures and future

  2014cites this paper
• An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias

  2014cites this paper
• Title : High-density lipoprotein , beta cells , and diabetes

  year unknowncites this paper